Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05910528 · ClinicalTrials.gov registry record · Phase 2
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 11
- Study locations
NCT05910528 is a Phase 2 study of Crohn's Disease that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 21 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT05910528, a Phase 2 study of Crohn's Disease, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 11
- Study locations
Study Summary
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
Conditions Studied
Interventions
- DRUG Afimkibart
Study Locations (11)
Other
- AZ Delta - Roeselare
- CHU de Nantes - Nantes
- Institut des MICI, Clinique Ambroise Paré - Neuilly-sur-Seine
- CHRU de Nancy Brabois - Vandœuvre-lès-Nancy
- Twoja Przychodnia-Szczecinskie Centrum Medyczne - Szczecin
- WIP Warsaw IBD Point Profesor Kierkus - Warsaw
Alabama
- Digestive Health Specialists - Dothan
Connecticut
- Medical Research Center of Connecticut, LLC - Hamden
Florida
- I.H.S Health Northwell Health - Kissimmee
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Clinical Research Institute of Michigan - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05910528
The ClinicalTrials.gov registry entry for NCT05910528 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (99% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Afimkibart is the first listed.
NCT05910528 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05910528 about?
NCT05910528 is a clinical study titled "Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease". This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
What is the current status of trial NCT05910528?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2023-07-24. Estimated completion is 2030-12-31.
What conditions does trial NCT05910528 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT05910528?
The interventions under investigation include: Afimkibart (DRUG).
Who is sponsoring clinical trial NCT05910528?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05910528 being conducted?
This trial has 11 study locations across Alabama, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.